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(SLE) (8%). Twenty-seven patients received allogeneic HCT (al-
loHCT) for SSC (n7), amyotrophic lateral sclerosis (n6), au-
toimmune cytopenias (n6), SLE (n2), autoimmune enteropathy
(n1) and unclassiﬁed AI (n3). The median age at HCT did not
differ by transplant type (41 vs. 36 years for autoHCT and allo-
HCT, respectively) and most patients (66%) had a good perfor-
mance score at HCT. The median time from diagnosis to trans-
plant was 58 and 34 months for autoHCT and alloHCT,
respectively. Irradiation-containing conditioning regimens were
used in 109 cases (61%) and cyclophosphamide either alone or in
combination with other agents without irradiation in 45 cases
(25%). Most autoHCT recipients received total body irradiation,
cyclophosphamide and anti-thymocyte globulin (64%). Peripheral
stem cell cells were the predominant graft type; and 56% of these
grafts were manipulated ex vivo (CD34 cell selection or T-cell
depletion). The probabilities of 100-day mortality were 10% (95%
conﬁdence interval [CI], 6-15%) and 17% (95% CI, 5-35%) after
autoHCT and alloHCT, respectively. Corresponding one-year
probabilities of overall survival were 89% (95% CI, 83-93%) and
75% (95% CI, 54-91%). One-year probability of overall survival
post-autoHCT were 96%, 82% and 73% for MS, SSC and SLE
respectively. In summary, these collective data from CIBMTR, MS
and SSC are the most common autoimmune disease indications for
HCT.
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AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AH-
SCT) FOR EARLY ONSET TYPE I DIABETES MELLITUS
Moraes, D.A.1, Oliveira, M.C.1, Stracieri, A.B.1, Couri, C.E.1,
Barros, G.M.1, Pieroni, F.1, Coutinho, M.A.1, Foss, M.C.1,
Simoes, B.P.1, Voltarelli, J.C.1 1Hospital das Clinicas/University of Sao
Paulo, Ribeirao Preto, Sa˜o Paulo, Brazil.
Introduction: Type I Diabetes mellitus (DM1) is an autoim-
mune disease that destroys pancreatic islet cells were insulin is
producted, leading to insulin dependence and chronic complica-
tions such as retinopathy, nephropathy, neuropathy and coronary
atherosclerosis.
Objectives: Evaluate the efﬁcacy and toxicity (phases I/II) of
high-dose cyclophosphamide (Cy) and rabbit anti-thymic globulin
(rATG) followed by rescue with AHSCT in patients with less than
6 weeks from diagnosis of type 1 Diabetes mellitus.
Materials and Methods: Stem cells were mobilized from the
bone marrow with Cy (2g/m2) and Filgrastim (10g/kg/d SC),
collected by leukapheresis and cryopreserved. Patients were con-
ditioned with Cy (50mg/kg x 4) and rATG (4.5 mg/kg), followed
by stem cell infusion.
Results: Since December 2003, 15 patients were enrolled in this
study. The medium age was 19.2 years, (14- 31 years), and the time
between diagnosis and mobilization was 34.7 days (24 to 49 days).
The mean hospitalization period was 24,2 days (16- 57 days) and
the average number of CD34 infused cells was 10.8106/kg
(5.8- 23.19106/kg). Neutrophil engrafted on days 8 to 10 (aver-
age of 9,3 days) and platelets engrafted on days 0 to 15 days
(average 12.3 days). There were no deaths. Most patients had
neutropenic fever, but only one developed serious complications
needing intensive care due to bilateral pneumonia, reversed with
antibiotic therapy and non-invasive ventilation. All patients were
using exogenous insulin therapy before mobilization, with an av-
erage dose of 0.38 Ul/kg (0.13 to 0.58 Ul/kg). In a mean follow-up
of 14.2 months (1- 31 months), insulin therapy was suspended in 12
patients from D-7 to D39 (average 32), two patients decreased
insulin dose (16 and 21% compared to the period before AHSCT)
and one patient remains using high dose insulin (1.7 Ul/kg/d). This
last patient was the only one that presented ketoacidosis pre-
AHSCT and received corticosteroids in the pre-conditioning pe-
riod. Six to twelve months after AHSCT, the peptide-C levels
considerably increased in 7 patients with clinical response and
glycated hemoglobin values are 7%.
Conclusion: These results indicate that high-dose immunosup-
pression associated with AHSCT may induce prolonged clinical
remission of Type 1 diabetes mellitus, without signiﬁcant toxicity.
The durability of response will be evaluated in longer follow-up.
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SERIAL SKIN BIOPSIES DEMONSTRATE REDUCED DERMAL FIBROSIS
AFTER AUTOLOGOUS HEMOPOIETIC STEM CELL TRANSPLANT (A-
HSCT) FOR SEVERE SYSTEMIC SCLEROSIS (SSS)
Shulman, H.M.1, Nash, R.A.1 1Fred Hutchinson Cancer Research Cen-
ter, Seattle, WA.
Background: In a multiinstitutional study, 34 patients with SSS
received high-dose immunosuppressive therapy followed by A-
HSCT. Serial evaluations included improvement in the modiﬁed
Rodnan skin score (mRSS, 51-0) and histologic dermal ﬁbrosis
score (DFS), grades 0-5.
Methods: 10 patients had 23 pre and post HSCT serial biopsies,
mean follow-up 4 years. Punch biopsies from each patient were
obtained from the same location on the lateral upper or lower arm.
The DFS was based on the depth and % of dermal homogeniza-
tion, size orientation and eosinophilia of ﬁbers, and interstitial
space between the fascicles in H&E -stained sections. The mRSS
showed a signiﬁcant improvement in 8/10 patients. The mean
decrease in mRSS of 34 patients’ (baseline 30.2) to ﬁnal evaluation
was 22.08 (-70.3%, and with a signiﬁcant linear decrease over time,
both p   0.0001). The DFS in 7 of 10 had 3 grades of
reduction. 3 had a ﬁnal DFS of 0 with reduction of dermal thick-
ness, loss of homogenization thinning and straightening of the
collagen bundles with an increase in interstitial space. The dermal-
epidermal border remained straightened with loss of rete ridges
and loss of elastica in the papillary dermis. The discordant ﬁnal
scores in patient 8, decrease in DFS without decrease in mRSS was
likely related to localized improvement of skin at site of biopsy.
Conclusion:
A-HSCT for SSS leads to remodeling of dermal collagen with
loss of sclerosis and corresponding improvements in the mRSS.
RESULTS: Assessment of dermal ﬁbrosis after A-HSCT for SSS
Patient
Baseline Final Score
mRSS/DFS Year/mRss/DFS
1 35/3 2/3/1
2 16/3 6/0/0
3 40/5 5/10/0
4 26/4 1/18/3
5 19/4 5/1/1
6 20/5 4/7/3
7 30/4 4/8/0
8 48/5 4/42/1*
9 44/5 4/10/1
10 29/5 3/12/2
AUTOLOGOUS TRANSPLANTS
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PREVENTION OF MUCOSITIS IN AUTO BMT/STEM CELL TRANSPLANT
PATIENTS
Klocke, J.1, Cannon, M.1, Gissenger, D.1, Devoe, C.1, John, V.1,
Bayer, R.-L.1 1North Shore University Hospital, 300 Community
Drive, Manhasset, NY.
It is estimated that 80% of patients who undergo high-dose
chemotherapy plus or minus radiotherapy prior to transplantation
develop mucositis. Mucositis is a painful complication, which can
lead to poor nutrition, increased use of narcotics, dehydration,
greater risk for infection and bacteremia, as well as altered quality
of life. Patients can have oral ulceration, epigastric discomfort,
diarrhea, rectal irritation, and bleeding. It is likely that the com-
plications of mucositis can contribute to increased lenght of stay
during stem cell transplantation.
The purpose of this study is to compare patients who received
Kepivance(palifermin) as part of their treatment with patients that
did not receive this medication during autologous stem cell trans-
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